Search

Search Constraints

You searched for: Author/Creator Cohen, Adam D

Search Results

1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Issue 2 (February 2020)

2. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Issue 10 (October 2020)

3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021)

4. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Issue 2 (February 2022)

6. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022)

7. Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Issue 12 (December 2018)

8. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

9. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

10. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)